Want to see IN:MEDPLUS full AI Analyst Report?
Top Page
MedPlus Health Services Ltd.
(MEDPLUS)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹702.00
▼(-13.20% Downside)
Action:Reiterated
Date:07/23/26
The score is anchored by decent underlying financial performance (growth and improved recent cash flow), but is pulled down materially by weak technicals (clear downtrend with bearish momentum) and a premium P/E valuation without dividend support.
Positive Factors
Omnichannel retail model
A combined neighborhood retail footprint plus digital ordering and home delivery creates durable customer convenience and repeat prescription flows. This omnichannel model supports higher reach, better inventory turnover and cross-sell, helping sustain revenue per customer and competitive positioning over time.
Negative Factors
Thin and volatile margins
Very low net margins limit the buffer against cost inflation or pricing pressure and make earnings sensitive to small revenue or cost swings. A sharp gross-margin decline in 2026 suggests structural mix or procurement pressures that, if persistent, could materially compress long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Omnichannel retail model
A combined neighborhood retail footprint plus digital ordering and home delivery creates durable customer convenience and repeat prescription flows. This omnichannel model supports higher reach, better inventory turnover and cross-sell, helping sustain revenue per customer and competitive positioning over time.
Read all positive factors
MedPlus Health Services Ltd. (MEDPLUS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹84.69B
Dividend YieldN/A
Average Volume (3M)39.52K
Price to Earnings (P/E)40.2
Beta (1Y)0.53
Revenue Growth16.79%
EPS Growth17.67%
CountryIN
Employees25,007
SectorGeneral
Sector StrengthN/A
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)17.55
Shares Outstanding120,137,060
10 Day Avg. Volume11,750
30 Day Avg. Volume39,524
Financial Highlights & Ratios
PEG Ratio1.00
Price to Book (P/B)5.10
Price to Sales (P/S)1.46
P/FCF Ratio24.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)18.13
Revenue Forecast (FY)₹80.52B
MedPlus Health Services Ltd. Business Overview & Revenue Model
Company Description
MedPlus Health Services Limited operates primarily as an Indian retailer of pharmaceutical products and diverse general merchandise. Its extensive product catalog includes vital health and wellness items such as prescription medications, vitamins,...
How the Company Makes Money
MedPlus primarily makes money by selling pharmaceutical and health products to consumers through its network of retail pharmacies and its online/omnichannel channels. The core revenue stream is product sales—especially prescription medicines—suppl...
MedPlus Health Services Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
67
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.29B | 68.92B | 61.36B | 56.25B | 45.58B | 37.79B |
| Gross Profit | 6.44B | 6.40B | 14.70B | 12.14B | 9.82B | 7.85B |
| EBITDA | 6.66B | 6.79B | 3.24B | 2.08B | 1.41B | 1.87B |
| Net Income | 2.10B | 2.20B | 1.50B | 654.73M | 497.63M | 958.02M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 39.33B | 33.60B | 30.05B | 27.97B | 25.94B |
| Cash, Cash Equivalents and Short-Term Investments | 6.13B | 4.62B | 4.40B | 1.65B | 2.89B | 6.58B |
| Total Debt | 0.00 | 14.24B | 11.20B | 10.10B | 9.05B | 8.15B |
| Total Liabilities | -19.75B | 19.58B | 16.20B | 14.27B | 13.06B | 11.77B |
| Stockholders Equity | 19.75B | 19.75B | 17.41B | 15.78B | 14.91B | 14.18B |
Cash Flow | ||||||
| Free Cash Flow | 2.71B | 4.04B | 4.95B | 593.38M | -785.95M | 521.68M |
| Operating Cash Flow | 3.13B | 5.27B | 5.54B | 1.44B | 904.10M | 1.70B |
| Investing Cash Flow | -680.55M | -1.59B | -3.32B | -827.99M | 4.29B | -7.03B |
| Financing Cash Flow | -1.22B | -2.55B | -2.28B | -1.98B | -1.70B | 4.40B |
MedPlus Health Services Ltd. Technical Analysis
Negative
808.80
Price Trends
811.83
Negative
839.65
Negative
824.15
Negative
Market Momentum
-36.99
Positive
28.76
Positive
24.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDPLUS, the sentiment is Negative. The current price of 808.8 is above the 20-day moving average (MA) of 752.36, below the 50-day MA of 811.83, and below the 200-day MA of 824.15, indicating a bearish trend. The MACD of -36.99 indicates Positive momentum. The RSI at 28.76 is Positive, neither overbought nor oversold. The STOCH value of 24.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDPLUS.
MedPlus Health Services Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹319.77B | 58.73 | ― | 0.63% | 14.29% | 5.55% | |
73 Outperform | ₹92.18B | 33.76 | ― | 1.65% | 21.09% | 65.51% | |
72 Outperform | ₹120.82B | 63.46 | ― | 0.21% | 23.64% | 29.96% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹17.10B | 16.86 | ― | 0.51% | 7.75% | 30.21% | |
52 Neutral | ₹84.69B | 40.17 | ― | ― | 16.79% | 17.67% | |
48 Neutral | ₹9.92B | 743.68 | ― | ― | 19.18% | ― |
* General Sector Average
IN:MEDPLUS
MedPlus Health Services Ltd.
690.55
-146.95
-17.55%
IN:KRSNAA
Krsnaa Diagnostics Limited
558.90
-272.67
-32.79%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,927.20
337.06
21.20%
IN:METROPOLIS
Metropolis Healthcare Ltd.
562.55
66.06
13.31%
IN:SASTASUNDR
Sastasundar Ventures Limited
313.55
34.55
12.38%
IN:THYROCARE
Thyrocare Technologies Ltd
597.90
157.36
35.72%
MedPlus Health Services Ltd. Corporate Events
MedPlus puts major CAPEX plans on hold after strategic review
Jul 23, 2026
MedPlus Health Services Ltd. has decided to place previously approved capital expenditure plans on hold following a review of its current business structure and market outlook. The shelved projects include the development of a Food Park by materia...
MedPlus asks exchanges to disregard erroneous investor presentation filing
Jul 22, 2026
MedPlus Health Services Limited has informed the BSE and NSE that an investor presentation filed on July 21, 2026 contained an unintended attachment due to an inadvertent error by the company. The filing occurred in the evening on both exchanges a...
MedPlus Subsidiary Faces Minor Karnataka Drug License Suspensions
Jul 15, 2026
MedPlus Health Services Ltd., a listed healthcare retailer, operates a broad network of pharmacy outlets across India through subsidiaries, including Optival Health Solutions Private Limited. Its core business centers on selling regulated pharmace...
MedPlus Subsidiary Faces Five-Day Drug License Suspension at Nashik Store
Jul 5, 2026
MedPlus Health Services Ltd. has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for the drug license of one retail store located in Samta Nagar, Nashik, Maharashtra. The suspension was issued b...
MedPlus Subsidiary Faces Short-Term Drug License Suspensions in Andhra Pradesh
Jun 24, 2026
MedPlus Health Services Ltd. has disclosed that its subsidiary Optival Health Solutions has received two suspension orders for drug licenses covering stores in Andhra Pradesh. The affected outlets, located on Kovvada Main Road and Bethemcherla Mai...
MedPlus Subsidiary Faces Three-Day Drug Licence Suspension at Telangana Store
Jun 20, 2026
MedPlus Health Services Ltd. has disclosed that its subsidiary Optival Health Solutions Private Limited received a three-day suspension of the drug licence for one pharmacy located in Vijaynagar Colony, Telangana, ordered by the Assistant Director...
MedPlus announces completion of tenure of two independent directors
Jun 10, 2026
MedPlus Health Services Ltd. has announced that Non-Executive Independent Directors Mr. Madhavan Ganesan and Mr. Murali Sivaraman have completed their first terms on the board as of the close of business on June 10, 2026. With the end of their ten...
MedPlus Subsidiary Faces Short-Term Drug License Suspensions at Two Telangana Stores
May 31, 2026
MedPlus Health Services Ltd. disclosed that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for drug licenses covering individual retail stores in Telangana. One store on Nareducharla Main Road faces a ...
MedPlus Subsidiary Faces Brief Drug Licence Suspensions for Two Karnataka Stores
May 23, 2026
MedPlus Health Services Ltd. disclosed that its subsidiary Optival Health Solutions Private Limited has received two suspension orders for drug licences covering individual retail pharmacy stores in Karnataka. The suspensions affect a store on Koh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.